Perrigo Completes Dermacosmetics Sale, Eyes Debt Reduction

What happened

Perrigo has closed the sale of its branded Dermacosmetics business to Karo Healthcare for total consideration of up to €332.6 million, receiving €305.6 million in upfront cash after working capital adjustments. The divestiture is a key pillar of management's Three-S plan to streamline the portfolio and sharpen focus on core self-care categories. Net proceeds of approximately €306 million are earmarked for debt reduction, a critical need given the company's net debt/EBITDA of roughly 7x and thin interest coverage. While the sale adds tangible progress to the restructuring narrative, the amount is modest relative to Perrigo's substantial debt load and does not materially alter the balance sheet risks. The contingent €27 million earn-out tied to sales milestones provides limited upside and underscores the uncertainty in the business's trajectory.

Implication

Investors should view the divestiture as a small step in the right direction, confirming management's commitment to portfolio simplification. However, with leverage still high and the Irish tax dispute unresolved, the equity remains speculative. The ~€306M cash infusion barely moves the needle against net debt exceeding $4B, and the company's ability to generate sustainable FCF and deliver on broader cost savings is what will drive re-rating. Until leverage trends comfortably below 5x and tax risks are clarified, maintain a cautious stance and monitor execution on Project Energize and Supply Chain Reinvention.

Thesis delta

The completed dermacosmetics sale is a modest positive that validates the Three-S plan's execution, but it does not alter the fundamental thesis of a highly leveraged, restructuring-dependent story. The thesis remains that Perrigo is a potential buy only if management can consistently deliver cost savings and FCF to reduce debt and margins expand. The sale is a tactical win, not a strategic game-changer, and the core risks—leverage, tax, and category softness—persist.